A new Type 2 Diabetes entrant must clear tirzepatide's SURPASS-2 efficacy bar or semaglutide's SELECT cardiovascular label, and price against an anchor the IRA has already cut twice.
Tirzepatide (Mounjaro, Eli Lilly) took 41% of new GLP-1 prescriptions within twelve months of its 2022 launch, on SURPASS-2 data showing 2.0–2.3% A1c reduction and 15–22% weight loss versus semaglutide's 1.86% and roughly 13kg. That is the efficacy bar a new incretin-class entrant must clear or exceed; incremental A1c improvement alone no longer moves share. Semaglutide has answered with a different lever entirely: its SELECT cardiovascular outcomes trial, a 20% MACE reduction in overweight and obese adults, has pulled payer attention beyond glycaemic control and toward organ-protection labeling, the same argument SGLT2 inhibitors have used since EMPA-REG (38% cardiovascular death reduction) and DECLARE-TIMI.
Whatever bar a new agent clears, it launches into a price architecture the Inflation Reduction Act has already reshaped twice. IPAY 2026 negotiated Januvia, Jardiance, and Farxiga down 66–79% from list, effective January 2026. IPAY 2027 extends to semaglutide itself, cut 71% to $274 for a 30-day supply from a list near $959, plus Janumet and Tradjenta. A pipeline entrant pricing at or above the pre-negotiation GLP-1 anchor is pricing against a reference point that will not exist by the time it launches; the commercial case has to be built against the post-MFP class economics, not the current one. ICER's 2019 Type 2 Diabetes assessment, which rated oral semaglutide cost-effective but less so than empagliflozin, is the value-tension precedent a new entrant's HEOR case will be measured against.
The Type 2 Diabetes bar a new entrant must clear — efficacy, label, and post-negotiation price
| Drug (Brand / INN) | Class | Key Trial Result | IRA Status | Market Position |
|---|---|---|---|---|
| Mounjaro / Zepbound (tirzepatide) | GIP/GLP-1 RA | SURPASS-2: A1c −2.3% vs sema −1.86%; weight −13kg | Not yet selected | 41% of new GLP-1 starts; efficacy benchmark |
| Ozempic / Rybelsus (semaglutide) | GLP-1 RA | SELECT: 20% MACE reduction | IPAY 2027 — $274/mo from ~$959 list | CV-label formulary priority; price reset 2027 |
| Jardiance (empagliflozin) | SGLT2 inhibitor | EMPA-REG: 38% CV death reduction | IPAY 2026 — $197/mo from $573 list | Organ-protection precedent; price anchor reset |
| Farxiga (dapagliflozin) | SGLT2 inhibitor | DECLARE-TIMI: HHF reduction | IPAY 2026 — $178/mo from $556 list | Renal-label expansion; price anchor reset |
Sources: FDA Drugs@FDA; NEJM SURPASS-2 (PMID 34170647); NEJM SELECT (PMID 37952131); NEJM EMPA-REG (PMID 26378978); NEJM DECLARE-TIMI 58 (PMID 30415602); CMS Medicare Drug Price Negotiation Program (IPAY 2026–2027); CDC National Diabetes Statistics Report; IQVIA prescription data 2023.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The SURPASS-2 A1c/weight-loss threshold a new GLP-1 or GIP/GLP-1 agent must clear
- Whether an organ-protection label (CV or renal) is now a precondition for premium pricing, not a bonus claim
- Positioning options against orforglipron, retatrutide, and CagriSema as they read out
Delivers
- The IPAY 2026/2027 Maximum Fair Price schedule and which classes are and are not yet selected
- Net-price anchor modeling for launch pricing given the semaglutide 2027 MFP
- Where the narrowing SGLT2/DPP-4 gap changes GLP-1 step-edit logic
Delivers
- Sizing of the 8.7M-undiagnosed and 97.6M-prediabetes case-finding pools
- Complication-driven (CKD, cardiovascular) segmentation that favors organ-protective mechanisms
- A payer step-edit and formulary-tier gap analysis for a new entrant's target cohort
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why clearing tirzepatide's SURPASS-2 bar or matching semaglutide's SELECT cardiovascular label is now table stakes, not differentiation
- The IRA price-anchor reset a new entrant is pricing against before it even launches
- Tirzepatide's 41% new-start share and semaglutide's SELECT-driven formulary priority
- SGLT2 organ-protection precedent (EMPA-REG, DECLARE-TIMI) and its role in current line-of-therapy guidelines
- The 8.7 million undiagnosed and 97.6 million prediabetes case-finding pools
- Complication-driven segmentation (CKD in ~1 in 3) favoring organ-protective mechanisms over A1c-only agents
- The IPAY 2026/2027 Maximum Fair Price schedule across six T2D agents and its formulary consequence
- Step-edit architecture requiring SGLT2 failure before GLP-1 access at major commercial payers
- Every population, pricing, and share figure sourced, confidence-rated and traceable
- Built to survive an internal challenge meeting
- Endocrinology and primary-care prescriber landscape and where new-entrant detailing should concentrate
- Specialty and retail pharmacy distribution readiness for an injectable or oral entrant
- Open questions on pricing against the post-MFP anchor and label-scope sequencing to close before launch strategy is locked
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment synthesises three independently-verified research angles into one launch-readiness view: incumbent competitive positioning, target-population epidemiology, and post-negotiation payer economics. Every factual claim traces to a primary source: FDA approval records, peer-reviewed trial publications, and CMS negotiation program documentation.
Type 2 Diabetes sources: FDA Drugs@FDA, NEJM SURPASS-2/SELECT/EMPA-REG/DECLARE-TIMI publications, CDC National Diabetes Statistics Report, American Diabetes Association Standards of Care and Economic Costs of Diabetes (Diabetes Care 2024), CMS Medicare Drug Price Negotiation Program IPAY 2026 and 2027 fact sheets, and the ICER Diabetes: Type 2 Evidence Report (2019).
- Incumbent efficacy and outcome data verified against FDA labels and the primary NEJM publications (SURPASS-2, SELECT, EMPA-REG, DECLARE-TIMI)
- IRA negotiation schedule and Maximum Fair Prices verified against CMS IPAY 2026 and IPAY 2027 fact sheets
- Population and complication-burden figures verified against the CDC National Diabetes Statistics Report and ADA Economic Costs of Diabetes 2024
- No figure carried from model memory; every parameter traceable to a named source in the assumption register
Frequently asked questions
Commission this assessment
AXLRx delivers Type 2 Diabetes launch-readiness assessments built for pharma and biotech commercial, access, and medical affairs teams preparing a pipeline asset. Custom assessment in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.